Epidemiological studies indicate that significant decreases in incidence of Alzheimer's disease may be obtained by targeting multiple middle-age risk factors. However, as dementia is unlikely to be diagnosed for decades, short-term outcome measures are required. AD biomarker changes precede clinical symptoms by many years, but their sensitivity to mid-life change remains unknown
Centre for Mental Health, Imperial College London, London UK 2 West London Mental Health Trust, London, UK 3 Neuroepidemiology of Ageing Research Unit, Imperial College, London W12 0NN; 4 Inserm, U1061 Neuropsychiatry, Montpellier, F-34093 France ; 5 Université de Montpellier 1, Montpellier, F-34000, France ; . In the face of a pandemic of dementia with predicted increases of 100% in developed countries between 2001 and 2020 (1), even small reductions in incidence, or delaying age of onset, are likely to have significant effects with regard to the enormous associated public health burden. The exact cause of the dementias remains unknown, however, epidemiological studies conducted over the past decade together suggest a complex interaction of exposures which contribute differentially to the probability and timing of disease onset and could be used as the basis for strategies to reduce risk and delay onset in the absence of specific disease-modifying treatments. While no single risk factor explains sufficient variance to be used individually as a basis for prevention, simulation studies in analytical epidemiology show that very significant decreases in population incidence might be obtained by targeting simultaneously multiple high risk factors (2, 3) . Exposure to many of these risk factors occurs in middle-age, for example hypertension and diabetes, suggesting that maximal impact is likely to be obtained by targeting middle-age populations with high risk of later life dementia. The pivotal question, however, is what to measure as an outcome indicator at this early stage given that clinical dementia is unlikely to be diagnosed for another 20 to 40 years.
Recent research on cognitive, neuroimaging and biological markers suggest that changes in several parameters may well precede overt clinical symptoms by not just many years but decades. Only one study to our knowledge has attempted to examine a biomarker at this very early stage; Alexopoulos et al. (4) have shown that young (mean age 24), healthy ApoE ε4 carriers have statistically significantly smaller hippocampal volumes than ApoE ε2 carriers. This observation is in support of our assumption, however, it requires confirmation in another data set and hippocampal size alone is insufficient evidence of early AD vulnerability. The aim of the PREVENT study is to examine the sensitivity of a wide range of candidate markers in mid-life in order to provide measures for future interventional research. There is increasing evidence that Aβ deposition in plaques precedes any sign of dementia by years if not decades (5, 6) . Though more accessible, plasma Aβ has given inconclusive results in terms of its predictive value (7) when compared to PIB PET (8) , whereas the predictive value of cerebrospinal-fluid Aβ 42 appear to directly reflect early brain deposition (9, 10) . Aβ42 paradoxically decreases in CSF with increasing deposition, hypothesized to be due to plaques acting as an Aβ42 "sink" preventing the transport of soluble Aβ42 to the CSF (11) . In the progression of pathology, plaque formation and the associated capture of central Aβ into the plaque with consequential lowering of CSF Aβ is considered a primary event that precedes the hyperphosphorylation of tau and neuronal disintegration. Aβ42 has thus has been recommended for use as an endpoint for future prevention programmes in younger adults (9) and has also been incorporated into the revised diagnostic criteria for pre-clinical dementia (12) . Alternatively amyloid may be intracerebrally observed and quantified through functional imaging of a radio-labelled Aβ ligand, however this method is far more expensive and less widely applicable (8, 10, 13) . b) Tau. Like Aβ 42 , tau and phosphorylated tau have emerged as important cerebrospinal fluid biomarkers for pre-clinical Alzheimer's disease. Increased concentrations of tau and phosphorylated tau correlate with both neuritic-plaque density and Braak NFT stage. In conjunction with Aβ 42 , tau and phosphorylated tau seem to be useful as prognostic biomarkers for conversion not only from cognitive impairment to dementia, but also from cognitively normal to mild cognitive impairment (8, 10, (13) (14) (15) .
As an indicator of neuronal death CSF tau is elevated in all types of neurodegenerative disease as well as post stroke. As the hyperphosphorylation of Tau is believed to be relatively specific to Alzheimer's disease, then the observation of elevated CSF pTau is thought to be a more specific early indicator of neurodegeneration secondary to AD. The combination of high tau and low Ab42 as a ratio is considered to have even greater accuracy for identifying Alzheimer's disease (16) (Petersen 2010 consistently observed in both humans and transgenic models (17, 18) with animal studies suggesting that a pro-inflammatory process may even be initiated before plaque deposition (17, 18) making it potentially the earliest pre-clinical indicator. Imaging studies provide further support for this hypothesis with observations of microglia activation before plaque formation. Further support comes from epidemiological observations of cognitive decline due to systemic infections and peri-operatively where elevation of systemic inflammatory proteins such as cytokines and inter-leukins may mediate a reactive activation of glial cells and consequent acceleration of oligomerisation (19) . Taken together, it would appear that inflammatory markers may elevate prior to a lowering of CSF Aβ (as a marker of Aβ oligomerisation) which in turn precedes the elevation of tau (as a marker of neurodegeneration).
The sequence of events is still, however, poorly understood although vital to the development of prevention programmes as it is likely to be a dynamic indicator differing according to distance from dementia onset at the time of CSF sampling. d) Structural brain imaging. Atrophy is particularly difficult to measure in the pre-clinical stages of dementia, when it superficially resembles the inconspicuous volume loss commonly observed among ageing individuals without neurodegeneration. Distinguishing such subtle differences is now possible using high-resolution quantitative magnetic resonance imaging (MRI) (20) which is able to predict not only progression from mild cognitive impairment to Alzheimer's disease (21) but also from normal cognition to mild cognitive changes (22) . Numerous cross-sectional and longitudinal MRI studies have now been conducted to identify markers which may indicate presymptomatic dementia. The focus of these studies has been on medial temporal atrophy, with the hippocampus and entorhinal cortex being affected before symptoms emerge (23, 24) . It has been estimated that subjects with cognitive difficulties in the years before dementia diagnosis already show hippocampal loss of 7 to 15% (25) and entorhinal cortex loss of 5 to 32% (26) . Although atrophy is often thought to be a downstream marker from amyloid in the cascade leading to dementia (27) , it appears to represent both neuronal loss and the presence of tau pathology, so may be directly related to the AD pathophysiological process (28) .
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1. That at mid-life (40 to 59 years) persons at high risk of dementia will show significant decreases in Aβ42 amyloid in plasma and CSF and increases in Tau and pTau (and their ratios) compared to low risk persons.
2.
High risk persons will show increased mid-life activity on pro-inflammatory cytokines IL-1α, IL1β, IL-18, IL-6, IL-8, TNF-α, IFN-γ, acute phase proteins (CRP, haptoglobin, sialic acid pr) and a long-term inflammatory marker (orosomucoid).
3. High risk persons at mid-life will have increased medial temporal lobe atrophy and white matter lesion volume. The MRI protocol will include whole brain volumetric T1 weighted images (1x1x1mm) for segmentation and volumetric analyses, dual echo and FLAIR sequences to allow identification and quantification of deep white matter hyperintensities and diffusion weighted imaging (minimum 16 directions) for identification of changes in normal appearing white matter and major tracts.
High risk persons will have poorer performance (both accuracy and information processing time)
on cognitive tasks reflecting transentorhinal and entorhinal cortex changes and hippocampal reduction as evidenced notably by visuospatial associative learning, spatial analysis, working and primary memory tasks.
5.
High risk persons will show evidence at mid-life of HPA and sympathetic axes dysregulation as evidenced by secretion of cortisol, and catecholamines, e.g. adrenaline, noradrenaline, dopamine and metabolites of degradation (metanephrine, nor-metanephrine). Data from this study were normally distributed, the APOE ε2 group having a hippocampal volume mean (SD) of 4.59cc (0.50cc). On this basis 50 subjects per group would allow us to show a mean difference of 0.327 between the groups; that is a mean of 4.263 in the APOE ε4 group with an alpha risk=0.05 and a power of 0.90. Examining data from a very large longitudinal population study of over 10 000 persons 65 and over (the 3 City Study, Montpellier) we observed the plasma biomarker Aβ42 to have the largest standard deviation likely to diminish power. Based on data from this study we therefore made a supplementary « worst case scenario » calculation. The mean (SD) level of plasmatic Aβ 42 in this study is 38.90 (12.326) , and on this basis 50 subjects in each of our groups would permit us to show a mean difference of 8.07 with an alpha risk=0.05 and 0.90 power. This is clearly poorer but we are unlikely to see levels this low in the PROGENY cohort with CSF rather than plasmatic Aβ.
Differences in biomarker levels

Procedures
Potentially eligible persons will be sent by post a Participant Information Sheet. All participants in the study are seen at the West London Cognitive Disorders Treatment and Research Unit in West London Mental Health Trust, West London. The other principal interest of this clinical service is that its catchment area is principally of Asian Indian origin, with very high rates of AD risk factors (diabetes, hypertension and stroke). On attendance, one of the study clinicians presents the project and takes Our group has also developed a visual short term memory binding paradigm that has been shown to predict familial AD 10-15 years before clinical symptoms in the absence of detectable changes in other neuropsychological tests (49)which will be applied as a supplementary cognitive test.
Upon completion, a blood sample is taken and a physical examination conducted including anthropometry and pulse/BP. Saliva samples are taken four times on the day of the clinical visit and participants will be asked to prepare a further four on a quiet day at home. Arrangements are also be made for CSF sampling and MRI. All procedures will be repeated at 24 months.
ApoE genotyping is performed immediately after consent has been given permitting the research study manager to allocate subjects to high, medium and low risk groups. Group allocation is known only to the manager, all other members of the research and clinical teams including the principal investigators being blind to group membership until all examinations have taken place both at recruitment and follow-up.
Ethics and dissemination of results
The principal ethical considerations relate to revelation of high AD risk status to participants and procedures to follow where pathology is detected. Following discussion with the London Ethics 11 Committee, it has been decided that as the risk status of potential participants is already known to them in that they have a parent with AD, it is not possible for them to be ignorant of their risk group, however, they will also be informed that this only places them at higher risk and does not necessarily mean they will develop the disorder in their life-time. Results from genetic testing will not, however, be transmitted as this is neither an inevitable or a treatable risk factor. Where pathologies are detected, the participant is informed and permission requested to forward the relevant information to the person's general practitioner.
Results from the PREVENT study will be published in peer reviewed journals. Should valid biomarkers be found, after the 150 participants are entered, recruitment will continue for participation in future intervention studies as well as to provide greater analytical power for both baseline and longitudinal analysis.
Analyses
The pre-clinical biomarkers of AD will be compared between the three groups of subjects using Student t test for continuous variables with an approximately normal distribution or using the Mann Whitney non parametric test for non normal continuous variables. The other characteristics of the subjects will also be compared between the two groups using the Student t test or the Mann Whitney test for continuous variables and the Chi square test for categorical variables. In case of differences on socio-economic variables or other confounding variables between the two groups adjusted group comparisons will be undertaken using analysis of variance or logistic regression.
CONCLUSIONS
The PREVENT Project will provide information on mid-life biomarker change in persons at high risk of late-onset AD. Should significant differences be found on any of the candidate measures, these biomarkers will then constitute end-points for the construction of a large population randomized
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Ethics and Dissemination
Detected pathologies are communicated to the participant's general practitioner with their permission.
Risk status by genotype will not be revealed. The results of the study will be published in peer reviewed journals and validated biomarkers used to construct a randomized controlled intervention study.
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In the face of a pandemic of dementia with predicted increases of 100% in developed countries between 2001 and 2020 (1), even small reductions in incidence, or delaying age of onset, are likely to have significant effects with regard to the enormous associated public health burden. The exact cause of the dementias remains unknown, however, epidemiological studies conducted over the past decade together suggest a complex interaction of exposures which contribute differentially to the probability and timing of disease onset and could be used as the basis for strategies to reduce risk and delay onset in the absence of specific disease-modifying treatments. While no single risk factor explains sufficient variance to be used individually as a basis for prevention, simulation studies in analytical epidemiology show that very significant decreases in population incidence might be obtained by targeting simultaneously multiple high risk factors (2, 3) . Exposure to many of these risk factors occurs in middle-age, for example hypertension and diabetes, suggesting that maximal impact is likely to be obtained by targeting middle-age populations with high risk of later life dementia. The pivotal question, however, is what to measure as an outcome indicator at this early stage given that clinical dementia is unlikely to be diagnosed for another 20 to 40 years.
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Recent research on cognitive, neuroimaging and biological markers suggest that changes in several parameters may well precede overt clinical symptoms by not just many years but decades. Only one study to our knowledge has attempted to examine a biomarker at this very early stage; Alexopoulos et al. (4) have shown that young (mean age 24), healthy ApoE ε4 carriers have statistically significantly smaller hippocampal volumes than ApoE ε2 carriers. This observation is in support of our assumption, however, it requires confirmation in another data set and hippocampal size alone is insufficient evidence of early AD vulnerability. The aim of the PREVENT study is to examine the sensitivity of a wide range of candidate markers in mid-life in order to provide measures for future interventional research.
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"sink" preventing the transport of soluble Aβ42 to the CSF (11) . In the progression of pathology, plaque formation and the associated capture of central Aβ into the plaque with consequential lowering of CSF Aβ is considered a primary event that precedes the hyperphosphorylation of tau and neuronal disintegration. Aβ42 has thus has been recommended for use as an endpoint for future prevention programmes in younger adults (9) and has also been incorporated into the revised diagnostic criteria for pre-clinical dementia (12) . Alternatively amyloid may be intracerebrally observed and quantified through functional imaging of a radio-labelled Aβ ligand, however this method is far more expensive and less widely applicable (8, 10, 13) . b) Tau. Like Aβ 42 , tau and phosphorylated tau have emerged as important cerebrospinal fluid biomarkers for pre-clinical Alzheimer's disease. Increased concentrations of tau and phosphorylated tau correlate with both neuritic-plaque density and Braak NFT stage. In conjunction with Aβ 42 , tau and phosphorylated tau seem to be useful as prognostic biomarkers for conversion not only from cognitive impairment to dementia, but also from cognitively normal to mild cognitive impairment (8, 10, (13) (14) (15) .
As an indicator of neuronal death CSF tau is elevated in all types of neurodegenerative disease as well as post stroke. As the hyperphosphorylation of Tau is believed to be relatively specific to Alzheimer's disease, then the observation of elevated CSF pTau is thought to be a more specific early indicator of neurodegeneration secondary to AD. The combination of high tau and low Ab42 as a ratio is considered to have even greater accuracy for identifying Alzheimer's disease (16)(Petersen 2010).
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 consistently observed in both humans and transgenic models (17, 18) with animal studies suggesting that a pro-inflammatory process may even be initiated before plaque deposition (17, 18) making it potentially the earliest pre-clinical indicator. Imaging studies provide further support for this hypothesis with observations of microglia activation before plaque formation. Further support comes from epidemiological observations of cognitive decline due to systemic infections and peri-operatively where elevation of systemic inflammatory proteins such as cytokines and inter-leukins may mediate a reactive activation of glial cells and consequent acceleration of oligomerisation (19) . Taken together, it would appear that inflammatory markers may elevate prior to a lowering of CSF Aβ (as a marker of Aβ oligomerisation) which in turn precedes the elevation of tau (as a marker of neurodegeneration).
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (31) . While there is currently little evidence as to which tests may be sensitive decades before diagnosis, histopathological studies point to the transentorhinal cortex as the first anatomical target followed by the entorhinal cortex and hippocampus. Evidence from lesion studies in humans and experimental animals (32, 33) and functional neuroimaging in normal adults (34) suggest on this basis that a decline in visuospatial associative learning to be a primary candidate for a very early marker. Longitudinal studies of prodromal dementia accompanied by blind assessment of MRI imaging suggests that diffuse cerebral and mediotemporal lobe atrophy in preclinical cases may also be evidenced by lower verbal memory and visuospatial analysis tasks before evidence on brain imaging (35) . While verbal learning tasks are often included in dementia assessment, the more complex processes of visuospatial information processing have to date been inadequately explored in pre-clinical studies. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 to insulin, except under a state of chronic glucocorticoid elevation, in which case they act to promote hepatic glycogen deposition and lipogenesis that leads to fat deposition, while raising insulin levels and impairing insulin actions on their receptors. It has been demonstrated (37) that whereas cardiovascular risk factors, type 2 diabetes and stroke form anthropometric, metabolic and haemodynamic clusters in correlation analyses in the general population, most of these risk factors also seem to form one tightly assembled cluster in individuals with HPA axis dysregulation suggesting this could be an overriding factor for the established risk factors targeted in this study and may thus constitute a very early biomarker of increased risk for cognitive decline. Disturbance on cortisol secretion has been reported in cognitive impairment and AD (38) (39) (40) (41) . In a mouse model of AD, glucocorticoid increased Aβ and tau pathology but an inverse weak association was found in a small clinical study of AD patients (42, 43) . Increase in cortisol levels and in mineralocorticoid receptor expression in the frontal cortex has been reported in AD and this correlated negatively to global cognitive function and positively to frontal cortex amyloid-β levels in Apo E4 carriers (44) . Higher cortisol levels have been associated with hippocampal atrophy. In healthy men, significant negative phenotypic associations were found between cortisol levels and the thickness of left dorsolateral and ventrolateral prefrontal regions, and right dorsolateral and medial orbital frontex (45) . Recent fMRI studies suggest a dynamically changing corticosteroid effects with reduced prefrontal and hippocampal responses as well as an altered coupling of the amygdala with the medial prefrontal cortex (46, 47) . Thus, while there is some evidence to suggest a major role of the stress system in early onset of dementia, this hypothesis has yet to be tested. A number of previous studies being crosssectional, focusing on elderly and cortisol secretion with a limited number of measurements and limited neuropsychological evaluation were indeed inconclusive regarding the early temporal relation between the whole functioning of stress axes and dementia.
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Upon completion, a blood sample is taken and a physical examination conducted including anthropometry and pulse/BP. Saliva samples are taken four times on the day of the clinical visit and participants will be asked to prepare a further four on a quiet day at home. Arrangements are also be made for CSF sampling and MRI. All procedures will be repeated at 24 months. ApoE genotyping is performed immediately after consent has been given permitting the research study manager to allocate subjects to high, medium and low risk groups. Group allocation is known only to the manager, all other members of the research and clinical teams including the principal investigators being blind to group membership until all examinations have taken place both at recruitment and follow-up.
Ethics and dissemination of results
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The principal ethical considerations relate to revelation of high AD risk status to participants and procedures to follow where pathology is detected. Following discussion with the London Ethics Committee, it has been decided that as the risk status of potential participants is already known to them in that they have a parent with AD, it is not possible for them to be ignorant of their risk group, however, they will also be informed that this only places them at higher risk and does not necessarily mean they will develop the disorder in their life-time. Results from genetic testing will not, however, be transmitted as this is neither an inevitable or a treatable risk factor. Where pathologies are detected, the participant is informed and permission requested to forward the relevant information to the person's general practitioner.
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Analyses
The pre-clinical biomarkers of AD will be compared between the three groups of subjects using analysis of variance for continuous variables with an approximately normal distribution or using the Kruskal-Wallis non parametric test for non normal continuous variables. The other characteristics of the subjects will also be compared between the three groups using the ANOVA or the Kruskal-Wallis tests for continuous variables and the Chi square test for categorical variables. In case of differences on socio-economic variables or other confounding variables between the three groups adjusted group comparisons will be undertaken using polytomous logistic regression.
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Introduction
Epidemiological studies indicate that significant decreases in incidence of Alzheimer's disease may be obtained by targeting multiple middle-age risk factors. However, as dementia is unlikely to be diagnosed for decades, short-term outcome measures are required. AD biomarker changes precede clinical symptoms by many years, but their sensitivity to mid-life change remains unknown
Methods and Analysis
PREVENT is a prospective cohort study examining biomarker status at mid-life in at least 150 persons genetically at high, medium or low risk of late-onset AD. Participants are children of persons with or without diagnosed AD allocated to high, medium and low risk groups according to parental clinical status and ApoE genotype. The biomarkers examined over two years are plasma and CSF Aβ42 amyloid, Tau and pTau, pro-inflammatory cytokines, acute phase proteins, medial temporal lobe atrophy, white matter lesion volume, cognitive performance related to transentorhinal and hippocampal functioning, and HPA and sympathetic axes regulation.
Ethics and Dissemination
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INTRODUCTION
In the face of a pandemic of dementia with predicted increases of 100% in developed countries between 2001 and 2020 (1), even small reductions in incidence, or delaying age of onset, are likely to have significant effects with regard to the enormous associated public health burden. The exact cause of the dementias remains unknown, however, epidemiological studies conducted over the past decade together suggest a complex interaction of exposures which contribute differentially to the probability and timing of disease onset and could be used as the basis for strategies to reduce risk and delay onset in the absence of specific disease-modifying treatments. While no single risk factor explains sufficient variance to be used individually as a basis for prevention, simulation studies in analytical epidemiology show that very significant decreases in population incidence might be obtained by targeting simultaneously multiple high risk factors (2, 3) . Exposure to many of these risk factors occurs in middle-age, for example hypertension and diabetes, suggesting that maximal impact is likely to be obtained by targeting middle-age populations with high risk of later life dementia. The pivotal question, however, is what to measure as an outcome indicator at this early stage given that clinical dementia is unlikely to be diagnosed for another 20 to 40 years.
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Selection of candidate biomarkers
a) Amyloid. There is increasing evidence that Aβ deposition in plaques precedes any sign of dementia by years if not decades (5, 6) . Though more accessible, plasma Aβ has given inconclusive results in terms of its predictive value (7) when compared to PIB PET (8), whereas the predictive value of cerebrospinal-fluid Aβ 42 appear to directly reflect early brain deposition (9, 10) . Aβ42 paradoxically decreases in CSF with increasing deposition, hypothesized to be due to plaques acting as an Aβ42 "sink" preventing the transport of soluble Aβ42 to the CSF (11) . In the progression of pathology, plaque formation and the associated capture of central Aβ into the plaque with consequential lowering of CSF Aβ is considered a primary event that precedes the hyperphosphorylation of tau and neuronal disintegration. Aβ42 has thus has been recommended for use as an endpoint for future prevention programmes in younger adults (9) and has also been incorporated into the revised diagnostic criteria for pre-clinical dementia (12) . Alternatively amyloid may be intracerebrally observed and quantified through functional imaging of a radio-labelled Aβ ligand, however this method is far more expensive and less widely applicable (8, 10, 13) . b) Tau. Like Aβ 42 , tau and phosphorylated tau have emerged as important cerebrospinal fluid biomarkers for pre-clinical Alzheimer's disease. Increased concentrations of tau and phosphorylated tau correlate with both neuritic-plaque density and Braak NFT stage. In conjunction with Aβ 42 , tau and phosphorylated tau seem to be useful as prognostic biomarkers for conversion not only from cognitive impairment to dementia, but also from cognitively normal to mild cognitive impairment (8, 10, (13) (14) (15) .
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (31) . While there is currently little evidence as to which tests may be sensitive decades before diagnosis, histopathological studies point to the transentorhinal cortex as the first anatomical target followed by the entorhinal cortex and hippocampus. Evidence from lesion studies in humans and experimental animals (32, 33) and functional neuroimaging in normal adults (34) suggest on this basis that a decline in visuospatial associative learning to be a primary candidate for a very early marker. Longitudinal studies of prodromal dementia accompanied by blind assessment of MRI imaging suggests that diffuse cerebral and mediotemporal lobe atrophy in preclinical cases may also be evidenced by lower verbal memory and visuospatial analysis tasks before evidence on brain imaging (35) . While verbal learning tasks are often included in dementia assessment, the more complex processes of visuospatial information processing have to date been inadequately explored in pre-clinical studies. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 to insulin, except under a state of chronic glucocorticoid elevation, in which case they act to promote hepatic glycogen deposition and lipogenesis that leads to fat deposition, while raising insulin levels and impairing insulin actions on their receptors. It has been demonstrated (37) that whereas cardiovascular risk factors, type 2 diabetes and stroke form anthropometric, metabolic and haemodynamic clusters in correlation analyses in the general population, most of these risk factors also seem to form one tightly assembled cluster in individuals with HPA axis dysregulation suggesting this could be an overriding factor for the established risk factors targeted in this study and may thus constitute a very early biomarker of increased risk for cognitive decline. Disturbance on cortisol secretion has been reported in cognitive impairment and AD (38) (39) (40) (41) . In a mouse model of AD, glucocorticoid increased Aβ and tau pathology but an inverse weak association was found in a small clinical study of AD patients (42, 43) . Increase in cortisol levels and in mineralocorticoid receptor expression in the frontal cortex has been reported in AD and this correlated negatively to global cognitive function and positively to frontal cortex amyloid-β levels in Apo E4 carriers (44) . Higher cortisol levels have been associated with hippocampal atrophy. In healthy men, significant negative phenotypic associations were found between cortisol levels and the thickness of left dorsolateral and ventrolateral prefrontal regions, and right dorsolateral and medial orbital frontex (45) . Recent fMRI studies suggest a dynamically changing corticosteroid effects with reduced prefrontal and hippocampal responses as well as an altered coupling of the amygdala with the medial prefrontal cortex (46, 47) . Thus, while there is some evidence to suggest a major role of the stress system in early onset of dementia, this hypothesis has yet to be tested. A number of previous studies being crosssectional, focusing on elderly and cortisol secretion with a limited number of measurements and limited neuropsychological evaluation were indeed inconclusive regarding the early temporal relation between the whole functioning of stress axes and dementia. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Data from this study were normally distributed, the APOE ε2 group having a hippocampal volume mean (SD) of 4.59cc (0.50cc). On this basis 50 subjects per group would allow us to show a mean difference of 0.327 between the groups; that is a mean of 4.263 in the APOE ε4 group with an alpha risk=0.05 and a power of 0.90. Examining data from a very large longitudinal population study of over 10 000 persons 65 and over (the 3 City Study, Montpellier) we observed the plasma biomarker Aβ42 to have the largest standard deviation likely to diminish power. Based on data from this study we therefore made a supplementary « worst case scenario » calculation. The mean (SD) level of plasmatic Aβ 42 in this study is 38.90 (12.326) , and on this basis 50 subjects in each of our groups would permit us to show a mean difference of 8.07 with an alpha risk=0.05 and 0.90 power. This is clearly poorer but we are unlikely to see levels this low in the PROGENY cohort with CSF rather than plasmatic Aβ. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 10 informed consent. Separate consent will be taken for CSF sampling so that participants may still be part of the PREVENT cohort for subsequent studies if they refuse the CSF extraction, however, only subjects accepting this procedure will be included in this first biomarker validation study. Consented participants are then interviewed by the study team who complete a standardized neuropsychiatric interview and a life-style questionnaire covering diet, occupation, work, education, life-time activity, adverse environmental exposures, alcohol and drug use. A battery of neuropsychometric tests focusing particularly on entorhinal and hippocampal functioning (the COGNITO battery) is administered using a tactile screen to permit recording of response latencies and qualitative aspects of performance (the manual for this test may be viewed on the following site: http://www.montp.inserm.fr/u1061/SiteU1061/PDF/COGNITO%20MANUAL%20ENGLISH.pdf).
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Procedures
Our group has also developed a visual short term memory binding paradigm that has been shown to predict familial AD 10-15 years before clinical symptoms in the absence of detectable changes in other neuropsychological tests (49)which will be applied as a supplementary cognitive test.
Ethics and dissemination of results
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